More recently, the receptor activator of nuclear factor kappa-B ligand inhibitor denosumab has also shown broad efficacy for SRE reduction in patients with bone metastasis from solid tumors [25]; however, denosumab was not available outside of a clinical trial during the period spanned by our retrospective database analysis. Here, TNFSF11 is linked to bone metastasis.